Genomic landscape and clinical characteristics of ERBB2/HER2 -mutated colorectal cancers
The Oncologist · 06.08.2026 · 31 (9)
DOI: 10.1093/oncolo/oyag302 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 31.07.2026. Verfasst von Muhammed Dogukan Aksu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, 55905, United States. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Molecular underpinnings and clinical characteristics of ERBB2/HER2-mutated colorectal cancers (CRCs) remain poorly understood. We aimed to comprehensively characterize the genomic landscape and clinical features of ERBB2/HER2-mutated CRC and to compare them with those of ERBB2/HER2-amplified CRC. Patients and methods We analyzed cBioPortal data from 4348 CRC patients with available ERBB2/HER2 profiling. Clinicodemographic features, microsatellite instability (MSI), tumor mutational burden, and alterations in 94 cancer-associated genes were evaluated using chi-square/Fisher’s exact test, Kruskal–Wallis test, and hierarchical clustering.
Results
ERBB2/HER2 putative driver mutations were identified in 95 patients (2.2%), amplifications in 87 (2.0%), and wild-type status in 4166 (95.8%). In the overall cohort, ERBB2/HER2-mutated tumors demonstrated significant KRAS enrichment (50.5%) compared to wild-type (37.7%; P = .014) and amplified tumors (18.4%; P < .001), alongside MSI enrichment (37.2% vs 1.6%; P < .001), elevated tumor mutational burden, and right-sided predominance. ERBB2/HER2-mutated tumors also showed broad driver co-alterations largely reflecting their MSI background. In contrast, ERBB2/HER2-amplified tumors exhibited left-sided predominance, with microsatellite stable (MSS)-restricted analyses revealing selective mutual exclusivity with KRAS (Log2 OR = −1.58; q = 0.019) and TP53 co-occurrence (Log2 OR = 2.04; q = 0.019). Hierarchical clustering confirmed that mutated and amplified tumors consistently occupy separate clusters across anatomical sites.
Conclusion
ERBB2/HER2 mutations and amplifications represent molecularly and clinically distinct subgroups. ERBB2/HER2-mutated tumors are characterized by an MSI-enriched, hypermutated background with frequent concurrent KRAS alterations, whereas amplified tumors exhibit selective KRAS mutual exclusivity and TP53 co-occurrence. These exploratory findings support alteration-specific therapeutic strategies in CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, 55905, United States.
- Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, United States.
- Division of Hematology and Oncology, Swedish Cancer Institute, Seattle, WA, 98104, United States.
- Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, 432120, United States.
- Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI, 48109, United States.
ORCID-Profile: Christine M Veenstra, Ibrahim Halil Sahin
Zitieren
APA
Aksu, M. D., Peniche, P. Z., Baytar, D. K., Jambunathan, B., Jan, Y. J. A., Hsieh, R., Rahman, S., Krauss, J. C., Veenstra, C. M., & Sahin, I. H. (2026). Genomic landscape and clinical characteristics of ERBB2/HER2 -mutated colorectal cancers. The Oncologist, 31(9). https://doi.org/10.1093/oncolo/oyag302
Vancouver
Aksu MD, Peniche PZ, Baytar DK, Jambunathan B, Jan YJA, Hsieh R, et al. Genomic landscape and clinical characteristics of ERBB2/HER2 -mutated colorectal cancers. The Oncologist. 2026;31(9). doi:10.1093/oncolo/oyag302
BibTeX
@article{Aksu2026,
author = {Aksu, Muhammed Dogukan and Peniche, Paola Zinser and Baytar, Doga Kahramangil and Jambunathan, Bhaghyasree and Jan, Yu Jen Alexander and Hsieh, Ronan and Rahman, Shafia and Krauss, John C and Veenstra, Christine M and Sahin, Ibrahim Halil},
title = {Genomic landscape and clinical characteristics of ERBB2/HER2 -mutated colorectal cancers},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {9},
doi = {10.1093/oncolo/oyag302}
}
EUVIMED